PRECORSE study: Seroprevalence of severe acute respiratory syndrome coronavirus 2 in the first trimester of pregnancy during the first wave of the COVID‐19 pandemic and subsequent pregnancy complications—A cohort study

PRECORSE study: Seroprevalence of severe acute respiratory syndrome coronavirus 2 in the first trimester of pregnancy during the first wave of the COVID‐19 pandemic and subsequent pregnancy complications—A cohort study

Synopsis The seroprevalence of severe acute respiratory syndrome coronavirus 2 among first‐trimester pregnant women January 1 to May 15, 2020, was 8.2%. There were no significant differences in complications in seropositive women.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of gynecology and obstetrics 2023-10, Vol.163 (1), p.326-328
Hauptverfasser: Aquise, Adriana, Rayo, Nieves, Fernández‐Buhigas, Irene, Alfonso, Ana, Pagola, Natalia, Rodriguez, Miguel, Miguel, Laura, Santacruz, Irene, Valor, Santiago, Poon, Liona C., Gil, María M., Santacruz, Belén
Format: Artikel
Sprache:eng
Schlagworte:
antibodies
coronavirus
COVID‐19
immunoglobulin
pandemic
pregnancy
SARS‐CoV‐2
seroprevalence
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Synopsis The seroprevalence of severe acute respiratory syndrome coronavirus 2 among first‐trimester pregnant women January 1 to May 15, 2020, was 8.2%. There were no significant differences in complications in seropositive women.
ISSN:0020-7292
1879-3479
DOI:10.1002/ijgo.15027